UA104517C2 - Тверда композиція, що є корисною в лікуванні інфекції вірусу гепатиту с, та способи її одержання - Google Patents

Тверда композиція, що є корисною в лікуванні інфекції вірусу гепатиту с, та способи її одержання

Info

Publication number
UA104517C2
UA104517C2 UAA201211694A UAA201211694A UA104517C2 UA 104517 C2 UA104517 C2 UA 104517C2 UA A201211694 A UAA201211694 A UA A201211694A UA A201211694 A UAA201211694 A UA A201211694A UA 104517 C2 UA104517 C2 UA 104517C2
Authority
UA
Ukraine
Prior art keywords
infection
manufacturing
solid composition
composition useful
treating hepatitis
Prior art date
Application number
UAA201211694A
Other languages
English (en)
Russian (ru)
Inventor
Бернд Ліпольд
Карін Розенблатт
Петер Хеліг
Раджив Гокхале
Ліна Прасад
Джонатан Міллер
Ерік А. Шмітт
Джон Б. Морріс
Original Assignee
Ебботт Леборетріз
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ебботт Леборетріз filed Critical Ебботт Леборетріз
Publication of UA104517C2 publication Critical patent/UA104517C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Abstract

Даний винахід характеризує тверду композицію, що містить аморфну сполуку І з активністю проти вірусу гепатиту С. Тверда дисперсія за даним винаходом містить також фармацевтично прийнятний гідрофільний полімер і фармацевтично прийнятну поверхнево-активну речовину. Сполука І може бути введена до складу аморфної твердої дисперсії, яка містить фармацевтично прийнятний гідрофільний полімер і фармацевтично прийнятну поверхнево-активну речовину.
UAA201211694A 2010-03-10 2011-03-08 Тверда композиція, що є корисною в лікуванні інфекції вірусу гепатиту с, та способи її одержання UA104517C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33996410P 2010-03-10 2010-03-10
PCT/US2011/027511 WO2011112558A2 (en) 2010-03-10 2011-03-08 Solid compositions

Publications (1)

Publication Number Publication Date
UA104517C2 true UA104517C2 (uk) 2014-02-10

Family

ID=44564075

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201211694A UA104517C2 (uk) 2010-03-10 2011-03-08 Тверда композиція, що є корисною в лікуванні інфекції вірусу гепатиту с, та способи її одержання

Country Status (27)

Country Link
US (1) US20110312973A1 (uk)
EP (1) EP2544689B1 (uk)
JP (2) JP5717768B2 (uk)
KR (1) KR101579079B1 (uk)
CN (2) CN104771364B (uk)
AR (1) AR081736A1 (uk)
AU (1) AU2011224558B2 (uk)
BR (1) BR112012022774A2 (uk)
CA (1) CA2792601C (uk)
CL (1) CL2012002500A1 (uk)
CO (1) CO6640208A2 (uk)
DO (1) DOP2012000245A (uk)
EA (1) EA021570B1 (uk)
EC (1) ECSP12012148A (uk)
ES (1) ES2613608T3 (uk)
GT (1) GT201200257A (uk)
IL (1) IL221833A (uk)
MX (1) MX2012010478A (uk)
MY (1) MY156888A (uk)
NZ (1) NZ602288A (uk)
PE (1) PE20130198A1 (uk)
SG (1) SG183985A1 (uk)
TW (1) TWI490218B (uk)
UA (1) UA104517C2 (uk)
UY (1) UY33265A (uk)
WO (1) WO2011112558A2 (uk)
ZA (1) ZA201207093B (uk)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA033370B1 (ru) * 2010-07-12 2019-10-31 Salix Pharmaceuticals Ltd Составы рифаксимина и их применение
AU2011352145A1 (en) * 2010-12-30 2013-07-18 Abbvie Inc. Phenanthridine macrocyclic hepatitis C serine protease inhibitors
US9044480B1 (en) 2011-03-03 2015-06-02 Abbvie Inc. Compositions and methods for treating HCV
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
CN103781496A (zh) * 2011-09-16 2014-05-07 艾伯维公司 用于治疗hcv的方法
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
AU2013201758B2 (en) * 2011-10-21 2014-11-27 Abbvie Ireland Unlimited Company Methods for treating HCV
AU2015200715A1 (en) * 2011-10-21 2015-03-05 Abbvie Ireland Unlimited Company Methods for treating HCV
EA201490836A1 (ru) 2011-10-21 2014-11-28 Эббви Инк. Комбинационное лечение (например, с abt-072 или abt-333) с помощью daa для применения при лечении hcv
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
GB2515941A (en) * 2011-10-21 2015-01-07 Abbvie Inc Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon
ES2529144B1 (es) * 2011-10-21 2015-10-26 Abbvie Inc. Combinación de aad para uso en el tratamiento del vhc
AU2015100285B4 (en) * 2011-10-21 2015-06-11 Abbvie Ireland Unlimited Company Methods for treating HCV
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
WO2014004674A2 (en) * 2012-06-27 2014-01-03 Abbvie Inc. Methods for treating hcv
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
WO2014011840A1 (en) 2012-07-12 2014-01-16 Abbvie Inc. Crystalline forms of an hcv inhibitor
SI3725778T1 (sl) 2012-09-11 2022-02-28 Medivation Prostate Therapeutics Llc Formulacije enzalutamida
MX360452B (es) 2012-10-19 2018-11-01 Bristol Myers Squibb Co Inhibidores del virus de la hepatitis c.
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014070974A1 (en) 2012-11-05 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014137869A1 (en) 2013-03-07 2014-09-12 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
JP6511432B2 (ja) 2013-03-15 2019-05-15 ギリアード サイエンシーズ， インコーポレイテッド Ｃ型肝炎ウイルスの大環状二環式阻害剤
CA2916912A1 (en) 2013-07-02 2015-01-08 Abbvie Inc. Methods for treating hcv
ES2927955T3 (es) 2013-09-11 2022-11-14 Univ Emory Composiciones de nucleótidos y nucleósidos y sus usos
US20150141351A1 (en) * 2013-11-18 2015-05-21 AbbVie Deutschland GmbH & Co. KG Solid Pharmaceutical Compositions
WO2015084953A1 (en) * 2013-12-04 2015-06-11 Abbvie Inc. Crystal forms
EP3089757A1 (en) * 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
US20150209403A1 (en) 2014-01-28 2015-07-30 Abbvie Inc. Dose Adjustment
MX2017015936A (es) * 2014-06-18 2018-04-18 Chugai Pharmaceutical Co Ltd Nueva composicion farmaceutica que comprende agentes tensioactivos no ionicos.
US20160074462A1 (en) 2014-09-11 2016-03-17 Abbvie Inc. Method of Treating HCV
WO2016134058A1 (en) 2015-02-18 2016-08-25 Abbvie Inc. Combinations useful to treat hepatitis c virus
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
AU2016314546C1 (en) * 2015-08-28 2021-07-22 Caliway Biopharmaceuticals Co., Ltd. Pharmaceutical composition used for reducing localised fat and use of pharmaceutical composition
CN109689063A (zh) 2016-04-28 2019-04-26 埃默里大学 含有炔烃的核苷酸和核苷治疗组合物及其相关用途
RS63751B1 (sr) 2016-09-30 2022-12-30 Salix Pharmaceuticals Inc Čvrsti disperzioni oblici rifaksimina
CA3056614C (en) 2017-03-15 2023-09-26 Cerecin Inc. Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto
US10004719B1 (en) 2017-05-30 2018-06-26 Taigen Biotechnology Co., Ltd. Solid dispersion formulation
WO2020112961A1 (en) * 2018-11-30 2020-06-04 Chemocentryx, Inc. Capsule formulations
WO2023154171A1 (en) * 2022-02-14 2023-08-17 Purdue Research Foundation Polymer salts for improved drug delivery from amorphous solid dispersions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
KR20050108420A (ko) * 2003-04-02 2005-11-16 베링거 인겔하임 인터내셔날 게엠베하 Ｃ형 간염 바이러스 프로테아제 억제제를 위한 약제학적조성물
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
CN1274300C (zh) * 2003-12-11 2006-09-13 中国科学院生物物理研究所 用于改善姜黄素溶出度和生物利用度的药物组合物及其制备方法
CA2578356C (en) 2004-09-24 2013-05-28 Boehringer Ingelheim Pharmaceuticals, Inc. A new class of surfactant-like materials
TW200716631A (en) * 2005-05-12 2007-05-01 Tibotec Pharm Ltd Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof
CN101273042B (zh) * 2005-07-29 2013-11-06 泰博特克药品有限公司 丙型肝炎病毒的大环抑制剂
UY30437A1 (es) * 2006-06-26 2008-01-31 Enanta Pharm Inc Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c
EP1880715A1 (en) * 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
MX2010006659A (es) * 2007-12-21 2010-07-05 Hoffmann La Roche Proceso para la preparacion de un macrociclo.
SG175692A1 (en) * 2008-04-15 2011-11-28 Intermune Inc Novel macrocyclic inhibitors of hepatitis c virus replication
US20110207660A1 (en) * 2008-08-07 2011-08-25 Schering Corporation Pharmaceutical formulations of an hcv protease inhibitor in a solid molecular dispersion
UY32099A (es) * 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
WO2010042834A1 (en) * 2008-10-09 2010-04-15 Anadys Pharmaceuticals, Inc. A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
US8232246B2 (en) * 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
US8476225B2 (en) * 2009-12-04 2013-07-02 Gilead Sciences, Inc. Antiviral compounds

Also Published As

Publication number Publication date
AU2011224558A1 (en) 2012-09-27
CN104771364A (zh) 2015-07-15
JP5890553B2 (ja) 2016-03-22
BR112012022774A2 (pt) 2017-09-12
SG183985A1 (en) 2012-10-30
JP2015145387A (ja) 2015-08-13
PE20130198A1 (es) 2013-03-24
JP2013522208A (ja) 2013-06-13
GT201200257A (es) 2014-09-26
KR20130048210A (ko) 2013-05-09
NZ602288A (en) 2014-02-28
JP5717768B2 (ja) 2015-05-13
CN103118681B (zh) 2015-02-18
MY156888A (en) 2016-04-15
CA2792601A1 (en) 2011-09-15
AU2011224558B2 (en) 2014-02-27
CO6640208A2 (es) 2013-03-22
AR081736A1 (es) 2012-10-17
ES2613608T3 (es) 2017-05-24
DOP2012000245A (es) 2013-02-15
CN104771364B (zh) 2018-05-25
ECSP12012148A (es) 2012-10-30
EP2544689A2 (en) 2013-01-16
KR101579079B1 (ko) 2015-12-21
ZA201207093B (en) 2013-05-29
EA201290892A1 (ru) 2013-03-29
WO2011112558A3 (en) 2012-01-05
CN103118681A (zh) 2013-05-22
TWI490218B (zh) 2015-07-01
EP2544689A4 (en) 2014-04-02
TW201202239A (en) 2012-01-16
CL2012002500A1 (es) 2012-12-07
WO2011112558A2 (en) 2011-09-15
EA021570B1 (ru) 2015-07-30
MX2012010478A (es) 2013-02-01
IL221833A (en) 2017-01-31
CA2792601C (en) 2015-09-29
US20110312973A1 (en) 2011-12-22
EP2544689B1 (en) 2017-01-11
UY33265A (es) 2011-10-31

Similar Documents

Publication Publication Date Title
UA104517C2 (uk) Тверда композиція, що є корисною в лікуванні інфекції вірусу гепатиту с, та способи її одержання
MY164607A (en) Solid compositions
MX2014008008A (es) Composiciones solidas que comprenden un inhibidor del virus de la hepatitis c.
WO2011056650A9 (en) Methods and compositions for treating and preventing viral infections
HK1166788A1 (uk)
WO2013173506A3 (en) Kinase inhibitors for use in the treatment of muscular degradation
MX341825B (es) Compuestos de heteroarilo y usos de los mismos.
WO2010090860A3 (en) Methods and compositions for treating bacterial infection
WO2010094009A3 (en) Methods and compositions for the treatment of ras associated disorders
IN2012DN01855A (uk)
WO2008153610A3 (en) Use of il-23 antagonists for treatment of infection
GB201213267D0 (en) Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases
WO2010017368A3 (en) Methods and compositions for treating anxiety
WO2010032011A3 (en) Anti-fungal therapy
MA37650A1 (fr) Forme amorphe d'un composé pyrimidinyl-cyclopentane inhibiteur de akt, compositions et procédés de celle-ci
WO2012017321A3 (en) Treatment for dyslipidemia
WO2011119954A3 (en) Antimicrobial silica composites
PH12017502426A1 (en) Solid pharmaceutical compositions for treating hcv
WO2010055474A3 (en) Antimicrobial compounds and compositions
WO2012082942A3 (en) Neuropeptide analogs, compositions, and methods for treating pain
PH12018500132A1 (en) Solid pharmaceutical compositions for treating hcv
WO2012139074A3 (en) Migrastatins and uses thereof
WO2012003030A3 (en) Methods of identifying & using anti-viral compounds
WO2011047390A3 (en) Heterocyclic benzoxazole compositions as inhibitors of hepatitis c virus
MX352620B (es) Polimeros de condensacion de acido mandelico.